AZN vs. ORCL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and ORCL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ORCL’s market capitalization of 666.59 billion USD is significantly greater than AZN’s 430.65 billion USD, highlighting its more substantial market valuation.
ORCL carries a higher beta at 1.32, indicating it’s more sensitive to market moves, while AZN (beta: 0.17) exhibits greater stability.
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, ORCL is a standard domestic listing.
| Symbol | AZN | ORCL |
|---|---|---|
| Company Name | AstraZeneca PLC | Oracle Corporation |
| Country | GB | US |
| Sector | Healthcare | Technology |
| Industry | Drug Manufacturers - General | Software - Infrastructure |
| CEO | Pascal Claude Roland Soriot | Safra Ada Catz |
| Price | 69.45 USD | 237.32 USD |
| Market Cap | 430.65 billion USD | 666.59 billion USD |
| Beta | 0.17 | 1.32 |
| Exchange | NASDAQ | NYSE |
| IPO Date | May 12, 1993 | March 12, 1986 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of AZN and ORCL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AZN
19.18%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
AZN’s Return on Equity of 19.18% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
ORCL
80.61%
Software - Infrastructure Industry
- Max
- 80.61%
- Q3
- 29.97%
- Median
- 2.84%
- Q1
- -8.35%
- Min
- -56.26%
In the upper quartile for the Software - Infrastructure industry, ORCL’s Return on Equity of 80.61% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
AZN
10.93%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AZN’s Return on Invested Capital of 10.93% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
ORCL
10.87%
Software - Infrastructure Industry
- Max
- 39.31%
- Q3
- 11.97%
- Median
- 1.67%
- Q1
- -7.10%
- Min
- -34.29%
ORCL’s Return on Invested Capital of 10.87% is in line with the norm for the Software - Infrastructure industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
AZN
14.14%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AZN’s Net Profit Margin of 14.14% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
ORCL
21.68%
Software - Infrastructure Industry
- Max
- 46.46%
- Q3
- 14.65%
- Median
- 2.66%
- Q1
- -7.70%
- Min
- -35.45%
A Net Profit Margin of 21.68% places ORCL in the upper quartile for the Software - Infrastructure industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
AZN
19.21%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AZN’s Operating Profit Margin of 19.21% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
ORCL
30.80%
Software - Infrastructure Industry
- Max
- 48.51%
- Q3
- 16.56%
- Median
- 4.48%
- Q1
- -6.43%
- Min
- -40.18%
An Operating Profit Margin of 30.80% places ORCL in the upper quartile for the Software - Infrastructure industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Return on Equity (TTM) | 19.18% | 80.61% |
| Return on Assets (TTM) | 7.31% | 7.39% |
| Return on Invested Capital (TTM) | 10.93% | 10.87% |
| Net Profit Margin (TTM) | 14.14% | 21.68% |
| Operating Profit Margin (TTM) | 19.21% | 30.80% |
| Gross Profit Margin (TTM) | 81.41% | 70.51% |
Financial Strength
Current Ratio
AZN
0.90
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AZN’s Current Ratio of 0.90 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
ORCL
0.75
Software - Infrastructure Industry
- Max
- 3.80
- Q3
- 2.25
- Median
- 1.51
- Q1
- 1.10
- Min
- 0.23
ORCL’s Current Ratio of 0.75 falls into the lower quartile for the Software - Infrastructure industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
AZN
0.77
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
AZN’s Debt-to-Equity Ratio of 0.77 is typical for the Drug Manufacturers - General industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ORCL
5.09
Software - Infrastructure Industry
- Max
- 2.56
- Q3
- 1.12
- Median
- 0.33
- Q1
- 0.05
- Min
- 0.00
With a Debt-to-Equity Ratio of 5.09, ORCL operates with exceptionally high leverage compared to the Software - Infrastructure industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio
AZN
7.95
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
AZN’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
ORCL
10.90
Software - Infrastructure Industry
- Max
- 32.21
- Q3
- 5.24
- Median
- 0.95
- Q1
- -17.99
- Min
- -50.82
ORCL’s Interest Coverage Ratio of 10.90 is in the upper quartile for the Software - Infrastructure industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 0.75 |
| Quick Ratio (TTM) | 0.70 | 0.75 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 5.09 |
| Debt-to-Asset Ratio (TTM) | 0.30 | 0.62 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.49 | 4.14 |
| Interest Coverage Ratio (TTM) | 7.95 | 10.90 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AZN and ORCL. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AZN
1.87%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AZN’s Dividend Yield of 1.87% is in the lower quartile for the Drug Manufacturers - General industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
ORCL
0.72%
Software - Infrastructure Industry
- Max
- 4.07%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.72%, ORCL offers a more attractive income stream than most of its peers in the Software - Infrastructure industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
AZN
63.60%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 63.60% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
ORCL
38.12%
Software - Infrastructure Industry
- Max
- 48.68%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ORCL’s Dividend Payout Ratio of 38.12% is in the upper quartile for the Software - Infrastructure industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Dividend Yield (TTM) | 1.87% | 0.72% |
| Dividend Payout Ratio (TTM) | 63.60% | 38.12% |
Valuation
Price-to-Earnings Ratio
AZN
28.12
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
At 28.12, AZN’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
ORCL
53.50
Software - Infrastructure Industry
- Max
- 107.77
- Q3
- 54.40
- Median
- 28.10
- Q1
- 18.03
- Min
- 5.32
ORCL’s P/E Ratio of 53.50 is within the middle range for the Software - Infrastructure industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
AZN
2.56
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AZN’s Forward PEG Ratio of 2.56 is within the middle range of its peers in the Drug Manufacturers - General industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
ORCL
2.34
Software - Infrastructure Industry
- Max
- 8.12
- Q3
- 3.94
- Median
- 2.13
- Q1
- 0.94
- Min
- 0.01
ORCL’s Forward PEG Ratio of 2.34 is within the middle range of its peers in the Software - Infrastructure industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
AZN
3.98
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AZN’s P/S Ratio of 3.98 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
ORCL
11.61
Software - Infrastructure Industry
- Max
- 18.25
- Q3
- 9.05
- Median
- 4.77
- Q1
- 2.30
- Min
- 0.11
ORCL’s P/S Ratio of 11.61 is in the upper echelon for the Software - Infrastructure industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
AZN
5.33
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
ORCL
32.55
Software - Infrastructure Industry
- Max
- 19.94
- Q3
- 10.91
- Median
- 6.33
- Q1
- 2.95
- Min
- 0.51
The P/B Ratio is often not a primary valuation metric for the Software - Infrastructure industry.
Valuation at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.12 | 53.50 |
| Forward PEG Ratio (TTM) | 2.56 | 2.34 |
| Price-to-Sales Ratio (P/S, TTM) | 3.98 | 11.61 |
| Price-to-Book Ratio (P/B, TTM) | 5.33 | 32.55 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.59 | -1691.86 |
| EV-to-EBITDA (TTM) | 13.82 | 33.69 |
| EV-to-Sales (TTM) | 4.46 | 13.24 |